Pharma Liebermann GmbH
Pharmaceutical Companies · Dillingen an der Donau
Pharma Liebermann GmbH is a pharmaceutical company based in Dillingen an der Donau, Baden-Württemberg, Germany. The company operates in the German pharmaceutical market and is regulated by the BfArM (Federal Institute for Drugs and Medical Devices).
Content in German
The detailed company information on this page is provided in the original German language. You can use your browser's built-in translation feature to view it in English.
Right-click on the page and select "Translate to English" or use the translation icon in your browser's address bar.
Pharma Liebermann GmbH Address & Contact
Pharma Liebermann GmbH Overview
Pharma Liebermann GmbH from Dillingen an der Donau is an innovative pharmaceutical company that has specialized in the distribution and logistics of pharmaceuticals in the German pharmacy market since its founding. With a clear focus on supplying pharmacies in Northern Swabia as well as nationwide, the company has established a solid position in the healthcare sector. The strategic orientation towards regional markets underscores the company's significance for medical care in Baden-Württemberg and beyond.
Services and Products
Pharma Liebermann markets a selection of finished pharmaceuticals that cover various therapeutic areas, including pain therapy, gastroenterology, dermatology, and respiratory diseases. In addition to prescription medications, the product portfolio also includes OTC (Over-the-Counter) products for self-medication. These include over-the-counter pain relievers, cough remedies, and preparations to support the immune system.
To ensure product quality, Pharma Liebermann collaborates closely with renowned manufacturers and wholesalers. The storage and logistics of pharmaceuticals are conducted in accordance with Good Distribution Practice (GDP) guidelines, ensuring consistently high quality and safety for end consumers. All offered pharmaceuticals have a valid approval according to the strict regulations of German pharmaceutical law, making the company a reliable partner in pharmaceutical distribution.
Regulatory Classification
Like many other companies in the pharmaceutical sector, Pharma Liebermann GmbH is subject to strict regulatory oversight. Compliance with the regulations for drug approval, the German Medicinal Products Act (AMG), and EU directives is fundamental for operational business. This ensures high standards in terms of safety, efficacy, and quality of the pharmaceuticals. Furthermore, Pharma Liebermann GmbH commits to regular training of its employees to best meet the latest regulatory requirements.
Location Dillingen an der Donau / Bavaria
Dillingen an der Donau, the district town of the same-named district, plays a central role in the pharmaceutical landscape of the region. Its geographical location between the major cities of Augsburg, Ulm, and Ingolstadt provides Pharma Liebermann with optimal access to a diverse pharmacy market. The good connections to highways and the proximity to other industrial centers promote not only logistics but also collaboration with other players in the healthcare industry.
The Northern Swabia region has established itself as increasingly attractive for pharmaceutical companies, supported by the presence of skilled professionals and specialized service providers. This offers Pharma Liebermann the opportunity to develop innovative solutions and expand its network in the healthcare sector. The regional significance is highlighted not only by economic figures but also by the qualitative improvement of medical care for the population.
Special Features of Pharma Liebermann GmbH
A prominent feature of Pharma Liebermann GmbH is its commitment to quality and safety in pharmaceutical supply. The company emphasizes transparent communication with its partners and customers to strengthen trust in the delivered products. In addition, it continuously invests in modern storage and logistics systems to meet the high demands of the market and to develop innovative solutions for the supply chain.
Another aspect that distinguishes Pharma Liebermann GmbH is its adaptability to the dynamic changes in the health market. Through market analysis and continuous monitoring of regulatory developments, the company remains well-informed and can proactively respond to new challenges, significantly enhancing its competitiveness.
Other pharmaceutical companies: Pharmaceutical Companies Overview | Pharmaceutical Companies Bavaria | Pharmaceutical Wholesale
```Frequently asked questions about Pharma Liebermann GmbH
What does Pharma Liebermann GmbH do?
Pharma Liebermann GmbH stellt pflanzliche Präparate zur äußeren Anwendung and homöopathische Komplexwithtel her. Ein Schwerpunkt is the Hochleisungssport, for den the company homöopathische Mittel develops, herstellt and disributes.
Pharmaceutical Companies in Germany
Related areas in healthcare
Pharmaceutical Companies by location
About Pharmaceutical Companies
Germany is one of the world's leading pharmaceutical nations, home to more than 1,000 pharmaceutical businesses employing approximately 130,000 people (vfa 2023). Companies operating in this sector develop, manufacture and distribute medicines across the entire value chain, from early-stage research and clinical trials through to market authorisation and commercial distribution. In Germany, every manufacturer of medicinal products must hold a manufacturing authorisation (Herstellungserlaubnis) issued under Section 13 of the AMG (Arzneimittelgesetz, Germany's Medicinal Products Act). Medicines may only be placed on the market after receiving approval from either BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Germany's Federal Institute for Drugs and Medical Devices, broadly comparable to the FDA in the United States or the MHRA in the United Kingdom) or the European Medicines Agency (EMA) via the centralised procedure. All manufacturing sites are subject to regular GMP (Good Manufacturing Practice) inspections carried out by the competent pharmaceutical supervisory authority of the relevant German federal state. The sector covers prescription-only medicines (Rx), non-prescription OTC products, generics, biosimilars and active pharmaceutical ingredients (APIs). This directory lists pharmaceutical manufacturers, marketers and licence holders across all German federal states with full contact details, addresses and phone numbers.
Germany's Pharmaceutical Industry
Germany is consistently ranked among the top five pharmaceutical markets worldwide, generating annual revenues exceeding EUR 50 billion and accounting for the largest share of pharmaceutical production in continental Europe. The industry is represented by two major associations: vfa (Verband Forschender Arzneimittelhersteller), which represents research-based companies, and BAH (Bundesverband der Arzneimittel-Hersteller), which represents the broader manufacturer base including OTC and self-medication products. German pharmaceutical companies cover the full spectrum from global innovator corporations and mid-sized specialty manufacturers to generic producers and biotech firms. The country is a world leader in active pharmaceutical ingredient (API) production, biologics manufacturing and pharmaceutical chemistry. Key therapeutic areas of strength include oncology, cardiovascular medicine, immunology, neuroscience and rare diseases. Germany also serves as a significant export hub, with pharmaceutical products among the country's leading export categories. The sector benefits from a highly skilled workforce, world-class university research institutions and a dense network of research hospitals (Universitätsklinika) that facilitate clinical trial activity.
Regulatory Framework: BfArM, EMA and the AMG
The legal foundation for pharmaceutical activity in Germany is the Arzneimittelgesetz (AMG, German Medicinal Products Act), which regulates the authorisation, manufacture, import, distribution, labelling and pharmacovigilance of medicinal products. For English-speaking readers unfamiliar with the German regulatory landscape: BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is the national competent authority responsible for approving medicines marketed only in Germany, supervising narcotics, and maintaining the pharmacovigilance database. BfArM is a higher federal authority (Bundesoberbehörde) subordinate to the Federal Ministry of Health (Bundesministerium für Gesundheit). For medicines approved via the centralised EU procedure, the European Medicines Agency (EMA) grants a single marketing authorisation valid in all 27 EU member states. Germany is also home to the Paul-Ehrlich-Institut (PEI), a second federal authority that specifically handles biological medicines including vaccines, blood products and gene therapy products. Manufacturing sites are inspected by state-level pharmaceutical supervisory authorities (Landesbehörden) to verify GMP compliance, with findings entered into the EudraGMDP database operated by the EMA.
Regional Pharmaceutical Clusters in Germany
Germany's pharmaceutical industry is geographically distributed across several major regional clusters. The Rhine-Main area around Frankfurt and Leverkusen in North Rhine-Westphalia is home to some of Germany's largest pharmaceutical sites, including facilities belonging to global corporations with long histories in German chemistry and pharmaceuticals. Bavaria (particularly Munich, Penzberg and Marburg) is a second major hub, especially strong in biotechnology and biologics production. Baden-Württemberg, including cities such as Mannheim, Heidelberg and Biberach an der Riss, is home to several significant research-based manufacturers. Hamburg and the northern German region have a cluster of specialty and generic manufacturers. Berlin has a growing biotech scene connected to its research universities and the Charité hospital. Hesse is notable for its proximity to Frankfurt's logistics infrastructure and several major API manufacturers. Smaller but significant clusters exist in Saxony (Leipzig, Dresden) and Lower Saxony, benefiting from proximity to university research centres and historically established chemical industry sites.
Drug Classes and Product Segments
German pharmaceutical companies cover all major drug classes. Prescription (Rx) products account for the largest share of revenue; generics manufacturers such as Stada, ratiopharm (Teva) and Hexal produce chemically equivalent alternatives after patent expiry, significantly reducing costs for the healthcare system. Biologics and biosimilars are gaining ground rapidly: monoclonal antibodies, insulin analogues and recombinant growth factors require specialised biotech manufacturing facilities. OTC products (over-the-counter), i.e. medicines available without a prescription, represent a multi-billion-euro market served by companies such as Bayer Consumer Health, Stada and Klosterfrau. Homeopathic preparations, herbal medicines and dietary supplements form further regulated segments. Digitalisation is increasingly shaping the sector: Digital Health Applications (DiGA) have been reimbursable since 2020, and AI-assisted drug development is significantly shortening time-to-market.
What does a pharmaceutical company do?
Pharmaceutical companies develop, produce and distribute medicines. They cover the entire value chain from research and clinical trials through to market launch and distribution. In Germany, they are supervised by BfArM (the Federal Institute for Drugs and Medical Devices, comparable to the FDA or MHRA).
How are pharmaceutical companies regulated in Germany?
Pharmaceutical companies in Germany must hold a manufacturing authorisation under Section 13 of the AMG (German Medicinal Products Act). All authorised medicines require approval from either BfArM or the European Medicines Agency (EMA). Regular GMP (Good Manufacturing Practice) inspections ensure quality standards are maintained.
Where can I find contact details for pharmaceutical companies in Germany?
Industry associations such as vfa (Association of Research-Based Pharmaceutical Companies) and BPI (Federal Association of the German Pharmaceutical Industry) maintain member directories. Many companies also list their key contacts directly on their websites. Sanoliste provides a searchable directory of pharmaceutical companies in Germany sorted by federal state and city.
How many pharmaceutical companies are there in Germany?
Germany is home to more than 1,000 pharmaceutical companies employing approximately 130,000 people, according to vfa (the Association of Research-Based Pharmaceutical Companies) 2023 data. The sector includes multinational corporations, mid-sized specialty firms, generic manufacturers and biotech startups.
What is BfArM and what does it regulate?
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is Germany's Federal Institute for Drugs and Medical Devices. It is a higher federal authority within the portfolio of the Federal Ministry of Health and is responsible for approving medicines for the German market, monitoring drug safety (pharmacovigilance), regulating narcotics and controlled substances, and overseeing medical devices in Germany. It is broadly comparable to the FDA in the United States or the MHRA in the United Kingdom.
What is the difference between BfArM approval and EMA approval?
Medicines in Germany can be approved through two main routes. BfArM grants national marketing authorisations valid in Germany, or decentralised and mutual recognition procedure approvals valid in multiple EU states. The EMA (European Medicines Agency) grants centralised marketing authorisations valid in all 27 EU member states simultaneously, typically used for innovative biologic medicines, oncology drugs and products for rare diseases.
What does GMP mean in the context of German pharmaceutical manufacturing?
GMP stands for Good Manufacturing Practice. In Germany and the EU, GMP compliance is a legal requirement for all pharmaceutical manufacturers under the AMG and the EU GMP Guidelines (EudraLex Volume 4). GMP covers all aspects of production including premises, equipment, personnel qualification, process validation, documentation and quality control. Compliance is verified by regular inspections from the competent state pharmaceutical supervisory authority.